Colorectal Cancer | Specialty

The colorectal cancer condition center is a comprehensive resource for clinical news and expert insights on colorectal cancer. Read more at OncLive.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Dr Saeed on the Rationale for Evaluating the Combination of Zanzalintinib Plus Atezolizumab vs Regorafenib in mCRC

November 11th 2025

Anwar Saeed, MD, discusses the rationale behind the STELLAR-303 trial evaluating zanzalintinib plus atezolizumab vs regorafenib in pretreated mCRC

Zanzalintinib Plus Atezolizumab Signals New Progress for Previously Treated mCRC

November 10th 2025

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

CSF1R Blockade With AMB-05X May Improve Tumor Control in ctDNA+ CRC

November 5th 2025

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC

October 25th 2025

Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.

Porustobart Plus Tislelizumab Yields Promising Responses in Pretreated MSS mCRC

October 23rd 2025

The phase 2 trial of porustobart plus tislelizumab showed antitumor activity and manageable safety in heavily pretreated MSS metastatic colorectal cancer.

Zanzalintinib Plus Atezolizumab Improves OS in Previously Treated Metastatic CRC

October 20th 2025

Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.

CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC

October 20th 2025

Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.

Sirexatamab Plus Bevacizumab/Chemo Improves Outcomes in DKK1-High mCRC

October 19th 2025

Sirexatamab plus bevacizumab shows promise in improving survival for patients with DKK1-high metastatic colorectal cancer.

Novel Immunotherapy Combination Destroys Colorectal Liver Metastases

October 16th 2025

Researchers from UCSF discovered that a combination of immunotherapies can reprogram the immune environment of colon cancer tumors in the liver.

FDA Grants Fast Track Status to NG-350A for pMMR Locally Advanced Rectal Cancer

October 15th 2025

NG-350A has been awarded fast track designation from the FDA for rectal cancer and is under further evaluation in the FORTRESS trial.

Real-World Evidence Complements Randomized Clinical Trial Data in Colorectal Cancer

October 10th 2025

Three experts share their perspectives on the complementary relationship between randomized clinical trials and real-world evidence in colorectal cancer.

OncLive Poll Results Reveal Most Anticipated GI Cancer Abstracts and Subtypes Ahead of ESMO 2025

October 10th 2025

See poll results highlighting the top gastrointestinal oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

October 6th 2025

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025

October 6th 2025

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

New Study Links Genetic Variation to Chemotherapy-Related Liver Damage in Patients With Colorectal Cancer Liver Metastases

October 6th 2025

A genetic factor may explain why some patients with colorectal cancer that has spread to the liver experience liver damage after chemotherapy.

Dr Elez on the Rationale for Evaluating QOL Outcomes With ICI Doublets in mCRC

September 30th 2025

Elena Élez, MD, PhD, discusses quality of life outcomes with combination checkpoint blockade in patients with microsatellite instability-high mCRC.

Real-World Evidence Complements and Contextualizes Randomized Clinical Trial Insights in Colorectal Cancer

September 30th 2025

While clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.

Dr Strickler on the Rationale for Evaluating Temab-A in Chemo-Refractory Metastatic CRC

September 26th 2025

John H. Strickler, MD, details the impetus for evaluating the novel c-Met–directed ADC Temab-A in refractory metastatic colorectal cancer.

FDA Grants Fast Track Designation to Alnodesertib Plus Irinotecan in ATM-Negative mCRC

September 24th 2025

Alnodesertib has received fast track designation from the FDA for patients with ATM-negative metastatic colorectal cancer.